BioSpace News Archive

Drug Development

Bluejay Therapeutics Advances in Hepatitis B and D Trials: Successfully Completes BJT-778 Phase 1a Study and Begins Phase 1b Trial Enrollment

Bluejay Therapeutics, a company dedicated to developing innovative treatments for viral and liver diseases, announces the successful completion of Phase 1a and enrolment of the initial Phase 1b cohorts for BJT-778, a potential best-in-class monoclonal antibody targeting hepatitis B surface antigen.

June 1, 2023
·
1 min read
AOP Health: Completed Study Strengthens Clinical Development Program for ropeginterferon alpha 2b (Besremi®) in polycythaemia vera

With the publication of the final results from the LOW-PV study in the New England Journal of Medicine Evidence conducted by Fondazione per la Ricerca dell’Ospedale di Bergamo under the leadership of Professor Tiziano Barbui, AOP Health announces an important advancement reinforcing its clinical development program for ropeginterferon alpha-2b in polycythaemia vera, a rare blood cancer.

June 1, 2023
·
4 min read
Policy

NMPA accepted Akeso’s ebronucimab (PCSK9) marketing application in two cardiovascular indications

Akeso Inc. announced that China’s National Medical Products Administration has accepted its New Drug Application for its fully human anti-PCSK9 monoclonal antibody ebronucimab for 2 indications 1) primary hypercholesterolemia and mixed hyperlipidemia, and 2) heterozygous familial hypercholesterolemia.

June 1, 2023
·
2 min read
Genetown

Scholar Rock to Present at the 2023 Jefferies Healthcare Conference

Scholar Rock announced that management will present at the Jefferies Healthcare Conference on Thursday, June 8, 2023, at 3:00 p.m. ET.

June 1, 2023
·
2 min read